Authored By: Sarah
15 Jul 2024

 Bronchiectasis Drugs Market Size to grow by USD 326.01 million between 2023-2027

According to a research report “ Bronchiectasis Drugs Market” by Product (Antibiotics, Expectorants, Others ) Distribution Channel (Offline, Online ) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2027 published by Technavio, the market size is estimated to grow by USD 326.01 million, at a CAGR of  9.98% during the forecast period. The global prevalence of various conditions, including humoral immunodeficiency, inflammatory bowel diseases, rheumatologic diseases, chronic obstructive pulmonary disease (COPD), cystic fibrosis, allergic bronchopulmonary aspergillosis, severe lung infections such as tuberculosis, and pneumonia, significantly contributes to the risk of bronchiectasis. For instance, the global prevalence of pneumonia is approximately 1.5%, or 150 cases per 10,000 people, while COPD, a leading cause of bronchiectasis, has seen a 30% increase in prevalence over the past decade, affecting over 70,000 individuals worldwide. This high incidence of underlying conditions necessitates a robust market for bronchiectasis drugs.

Browse market data tables, figures, and in-depth TOC on “Bronchiectasis Drugs Market” by Product (Antibiotics, Expectorants, Others ) Distribution Channel (Offline, Online ) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2027. Download Free Sample

 

By Product, the Antibiotics segment is projected to dominate the market size in 2024

In the Bronchiectasis Drugs market, offline distribution channels represent a significant segment for selling and supplying bronchiectasis medications outside the online marketplace. These channels include pharmacies, hospitals, clinics, and other healthcare facilities. Offline distribution is crucial as it caters to patients who prefer purchasing medications in person or require prescriptions from healthcare professionals. This distribution model offers several advantages, such as accessibility to patients, especially those without Internet access, and the opportunity for direct interaction between patients and healthcare providers for guidance and advice. Offline distribution channels ensure the availability of bronchiectasis drugs in convenient locations, enhancing patient convenience and adherence to treatment regimens.

By Distribution Channel, Offline  segment is expected to hold the largest market size for the year 2024

The antibiotic segment represents a significant portion of the bronchiectasis drug market, with a diverse range of off-label treatments including azithromycin, erythromycin, doxycycline, amoxicillin, ciprofloxacin, and macrolides. These antibiotics are extensively utilized in the treatment of bronchiectasis due to the lack of approved drug therapies for this condition. Antibiotics play a pivotal role in interrupting the persistent infection cycle, reducing inflammation, and mitigating airway damage. The application of antibiotics in bronchiectasis treatment is categorized into exacerbation treatment, chronic suppressive treatment, and eradication treatment. Antibiotics administered during exacerbations contribute to decreasing serum C-reactive protein concentrations, mucus volume, and bacterial density, ultimately leading to symptomatic improvement.

North America is forecasted to hold the largest market size by region in 2024

The North American bronchiectasis drugs market is predominantly fueled by the substantial sales of off-label drug therapies, which have been approved for managing other chronic respiratory conditions. The market's growth is further propelled by the rising prevalence of chronic respiratory diseases, including bronchiectasis. Notably, the elderly population exhibits a significantly high and escalating incidence of bronchiectasis, with the US reporting approximately 1,200 cases per 100,000 population over the last decade. In 2005, the prevalence was significantly lower, with around 16 cases per 100,000 individuals in the 18-34 age group and approximately 280 cases per 100,000 among those aged over 75 years. This represents a fourfold increase from the past, underscoring the market's substantial growth potential.

The Bronchiectasis Drugs Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • AbbVie Inc.
  • Akorn Operating Co LLC
  • Amneal Pharmaceuticals Inc.
  • Aurobindo Pharma Ltd.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Dr Reddys Laboratories Ltd.
  • Endo International Plc
  • GlaxoSmithKline Plc
  • Hikma Pharmaceuticals Plc
  • Lupin Ltd.
  • Neopharma Corp.
  • Pfizer Inc.
  • Reckitt Benckiser Group Plc
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Virtus Pharmaceuticals LLC
  • Wockhardt Ltd.
  • Zydus Lifesciences Ltd.
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

The Bronchiectasis Drugs Market is witnessing significant growth due to the increasing prevalence of chronic lung diseases, particularly among smokers and drinkers. High healthcare costs and trade regulations pose challenges to market growth. The American Thoracic Society (ATS) has emphasized the need for targeted therapies to manage respiratory problems associated with bronchiectasis. Telemedicine is emerging as a cost-effective solution to increase access to care for patients in remote areas. The Antibiotics category dominates the market due to the frequent infections experienced by bronchiectasis patients. Awareness initiatives and the availability of generic medications are also contributing to market growth. Otolaryngologists play a crucial role in diagnosing and managing bronchiectasis. Targeted therapies, such as mucolytics and bronchodilators, are expected to gain popularity in the coming years. However, stringent regulatory requirements and the high cost of these therapies remain key challenges.

Market Research Overview

Title: Bronchiectasis Drugs Market: Innovative Therapies, Pharmacological Interventions, and Disease Management Strategies Bronchiectasis is a chronic respiratory condition characterized by persistent cough, recurrent infections, and mucus production due to damage to the bronchial tubes. With an increasing prevalence of bronchiectasis, driven by aging populations and underdiagnosis, the need for effective therapeutic interventions is on the rise. The bronchiectasis drugs market is witnessing significant growth due to the development of innovative therapies, pulmonary rehabilitation, and pharmacological interventions. Disease management strategies, including airway clearance techniques and medication options, are essential for managing symptoms and preventing disease progression. Key players in the healthcare market, such as Insmed Incorporated, are developing novel drugs like Brensocatib for idiopathic bronchiectasis, addressing unmet medical needs. Pharmaceutical research is focusing on small molecules, monoclonal antibodies, and targeted therapies like biologics to improve patient care. The antibiotic segment dominates the bronchiectasis drugs market due to the disease's infection-related pathophysiology. However, alternative treatment options like bronchodilators, inhaled corticosteroids, and mucolytics are also essential for managing symptoms. Regulatory obstructions and high healthcare costs are challenges in the bronchiectasis drugs market. Collaborations between industry players and healthcare providers are crucial for overcoming these challenges and expanding product approvals, revenue pockets, and geographic reach. Education and awareness initiatives, such as World Bronchiectasis Day, are essential for improving diagnostics and reducing the stigma surrounding this chronic respiratory ailment. Telemedicine and targeted therapies are technological innovations that can enhance patient care and accessibility. The bronchiectasis drugs market is expected to grow significantly in the coming years, driven by the increasing prevalence of respiratory disorders, medical innovation, and the need for effective therapeutic solutions.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio
Document